Zhongnan Medical Journal Press

Home Results

A total of 15 result was found. Results that relate to Survival

The effect of marital status on patients with laryngeal squamous cell carcinoma: using data from the SEER database

Published on New Medicine 2022,32(1):424-433.
5104 times 1769 times

Gao-Ya WANG Si-Rong ZHU Min-Lan YANG Xiao-Ping MING Xiu-Ping YANG Xiong CHEN

Laryngeal squamous cell carcinoma Prognostic factors Marital status Survival analysis SEER database
Details
Differentially expressed miRNAs in Luminal and Basal-like breast cancer

Published on New Medicine 2021,31(1):178-185.
8109 times 3275 times

Ming-Juan ZHAO Jiang-Bo LIU Qian-Qian YUAN Tong DENG Qiao HUANG Gao-Song WU Cheng FANG

miRNAs Luminal breast cancer Basal-like breast cancer Survival analysis
Details
Application of Excel and Visual Basic program language in exploring the impact of MicroRNA-501 on the survival of patients with lung squamous cell carcinoma

Published on New Medicine 2020,30(1):336-344.
5010 times 2681 times

Zhi-Yuan HUANG Wen-Hao JIANG Fu-Gui YANG Lei ZHU Lin DONG Ling-Wei WANG Ming-Hao FENG Liang WEI Guang-Xue WANG Qin-Chuan LI

Excel software Visual Basic program tools MicroRNA miR-501 Survival analysis The product limit method Log-rank test
Details
The effect of age on prognosis and distant metastasis in patients with stage IV rectal cancer

Published on Journal of Mathematical Medicine 2023,36(2):118-126.
1679 times 630 times

Ye QIU Fu-Ping ZHONG Miao WANG Tian-He HUANG Wen-Jing LIANG Yong-Chang WEI

Stage IV rectal cancer Prognosis Metastasis Age SEER database Survival analysis
Details
Survival analysis of outpatients with moderate and severe cancer pain based on phar-maceutical follow-up

Published on Chinese Journal of Pharmacoepidemiology 2023,32(5):506-512.
1318 times 449 times

Ke-Qiang CAI Xiu-Hua ZHANG Ying WANG Xin-Lei ZHUANG

Cancer patients Outpatient department Survival analysis Pharmaceutical follow-up
Details
Financial burden after pediatric liver transplantation in a hospital from 2017 to 2021

Published on Chinese Journal of Pharmacoepidemiology 2023,32(10):1089-1096.
1927 times 513 times

Ran-Jia LIU Ji-De XU Dan-Dan LI Ye XU Li-Ying SUN Xiang-Li CUI Zhi-Jun ZHU

Pediatric liver transplantation Financial burden of disease Direct medical cost Indirect cost Immunosuppressant Follow up Long-term survival
Details
Effect of platinum-containing regimen combined with chemotherapy on the survival of elderly patients with advanced non-small cell lung cancer

Published on Journal of Mathematical Medicine 2023,36(12):899-905.
1825 times 739 times

Xue-Xing WANG Yuan HE Jie CHU Yu-Feng WANG

Non-small cell lung cancer Retrospective cohort study Chemotherapy The elderly Survival analysis
Details
Cost-utility analysis of tislelizumab versus sorafenib as first-line treatment for advanced unresectable hepatocellular carcinoma

Published on Frontiers in Pharmaceutical Sciences 2024,27(1):109-116.
1583 times 564 times

SU Zhan CHE Jinhui PEI Ruifeng

Hepatocellular carcinoma Tislelizumab Sorafenib Partition survival model Pharmacoeconomic analysis
Details
Real-world study of sintilimab combined with bevacizumab in patients with advanced hepatocellular carcinoma

Published on Frontiers in Pharmaceutical Sciences 2024,27(3):485-490.
1731 times 854 times

SU Zhan CHE Jinhui PEI Ruifeng

Advanced hepatocellular carcinoma Sintilimab Bevacizumab Clinical efficacy Safety Overall survival Progression-free survival
Details
Partitioned survival model of pharmacoeconomics evaluation of oncology therapy in R language

Published on Journal of Mathematical Medicine 2024,37(4):240-251.
3145 times 796 times

LIU Jiayi LI Wei

R language Pharmacoeconomics evaluation Health economic evaluation Partitioned survival model Oncology treating drugs
Details
Efficacy and safety of tislelizumab combined with sorafenib in the treatment for unresectable hepatocellular carcinoma

Published on Frontiers in Pharmaceutical Sciences 2024,27(8):1136-1342.
1885 times 379 times

JIANG Jinghua HU Yiting

Tirilizumab Sorafenib Unresectable Hepatocellular carcinoma Objective response rate Disease control rate Progression-free survival Overall survival
Details
Expression of ADAM12, MUC3A and MUC17 in gastric cancer and analysis of survival prognosis

Published on Journal of Mathematical Medicine 2024,37(8):600-609.
2965 times 496 times

LI Yuxin GUO Tangxi WEI Yongchang

ADAM12 MUC3A MUC17 Gastric cancer Survival prognosis Targeted therapy
Details
Effects of statins on survival outcomes in patients with metastatic renal cell carcinoma

Published on Frontiers in Pharmaceutical Sciences 2024,28(1):28-33.
1480 times 318 times

GAO Shiliang HE Xiaoqi ZHENG Huijie YANG Di YU Mingzhu

Metastatic renal cell carcinoma Statins Survival outcomes Overall survival Progression-free survival Objective response rate Disease control rate
Details
Cost-utility analysis of pembrolizumab combined with chemotherapy for advanced malignant pleural mesothelioma

Published on Chinese Journal of Pharmacoepidemiology 2024,33(10):1107-1114.
1441 times 292 times

HU Yunjia ZOU Keqing HOU Yanhong

Pembrolizumab Chemotherapy Advanced malignant pleural mesothelioma Partitioned survival model Cost-utility analysis Pharmacoeconomic evaluation
Details
Long-term survival of multifocal glioblastoma treated with combined tumor treating fields and chemoradiotherapy: a case report

Published on Journal of Mathematical Medicine 2024,37(11):880-887.
1127 times 218 times

JIN Jieying HUANG Yong CHEN Yuanyuan WU Qiuji ZHONG Yahua

Glioblastoma multiforme Tumor treating fields Chemoradiotherapy Survival Case report
Details